If you weren’t already aware, the era of emerging biotechs has arrived.
Last year, these companies accounted for 72% of 2,853 late-stage drugs in the collective industry pipeline, up from 65% of 2,083 medicines in 2013. Meanwhile, 47% of the therapies launched in the U.S. in 2018 were attributed to emerging biotechs, which were defined as spending less than $200 million annually on R&D and having less than $500 million in revenue.
And here is another interesting detail: Emerging biotechs patented almost two-thirds of new drugs that were launched in 2018, while big pharma patented one-quarter, according to a new report by the IQVIA Institute for Human Data Science. Overall, there were 59 new active drugs launched last year, which also happened to be a larger number than at any time during the past five years.